Xiong Xiaozhong, Ho Melody, Jaber Karim, Mishra Rashmi, Charytan Amalya, Zaidan Nadim, Schlamp Florencia, Fishman Glenn I, Nazzal Lama
Division of Nephrology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
bioRxiv. 2025 May 14:2025.05.14.654014. doi: 10.1101/2025.05.14.654014.
Accumulation of oxalate in patients with chronic kidney disease (CKD) is associated with CKD progression and increased risk of cardiac death. Whether reducing plasma or urine oxalate slows CKD progression and prevents cardiovascular complications remains unexplored. We colonized the intestines of control and CKD mice with (), an oxalate-degrading microorganism. The mice were fed with the oxalate precursor hydroxyproline for 23 weeks at which time we assessed pathological changes in the kidney and heart. We demonstrate that reduces plasma oxalate (pOx) and creatinine levels, mitigates inflammation and fibrosis in the kidney, and reduces pathologic cardiac remodeling in the hearts of CKD mice. RNA-seq analysis of ventricular tissue of CKD mice reveals dysregulated expression of metabolic pathways while colonization reverses these changes. These findings demonstrate that oxalate accumulation plays a role not only in CKD progression but also in associated cardiovascular complications and suggest that strategies to reduce plasma oxalate levels may have therapeutic benefit.
慢性肾脏病(CKD)患者体内草酸盐的蓄积与CKD进展及心脏死亡风险增加相关。降低血浆或尿液草酸盐是否能减缓CKD进展并预防心血管并发症仍未得到探索。我们用一种草酸盐降解微生物()定殖于对照小鼠和CKD小鼠的肠道。给小鼠喂食草酸盐前体羟脯氨酸23周,此时我们评估肾脏和心脏的病理变化。我们证明,()可降低血浆草酸盐(pOx)和肌酐水平,减轻肾脏炎症和纤维化,并减少CKD小鼠心脏的病理性心脏重塑。对CKD小鼠心室组织的RNA测序分析揭示代谢途径的表达失调,而定殖()可逆转这些变化。这些发现表明,草酸盐蓄积不仅在CKD进展中起作用,还在相关心血管并发症中起作用,并提示降低血浆草酸盐水平的策略可能具有治疗益处。